Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated February 02, 2022, titled "Alembic Pharmaceuticals receives USFDA Tentative Approval for Fesoterodine Fumarate Extended-Release Tablets, 4 mg and 8 mg".
Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated February 02, 2022, titled "Alembic Pharmaceuticals receives USFDA Tentative Approval for Fesoterodine Fumarate Extended-Release Tablets, 4 mg and 8 mg".